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Climbing their way through their maternity. 
At steeper gradients they rest awhile 
And ponder every step their Herculean task. 
Prepare for last assault, and summit reached 
They sit and stare, at all the beauty lying there 
And wrap the sun, the moon, the stars 




In a retrospective study, a group of 77 pregnant women who had 
positive diabetic screening tests and negative oral glucose tolerance 
tests (OGTTs) was compared with a group of 251 pregnant women who had 
negative screening tests. Statistically significant differences were 
evident with respect to age >_ 35 years, obesity, history of stillbirth(s), 
neonatal respiratory difficulties, and birth weight >. 4000 grams; however, 
when the birth weights were corrected for gestational age, sex, mother's 
height, mother's weight, and parity, no macrosomia was evident. No 
significant differences were noted with respect to 32 other variables. 
The probability of occurrence of significant differences due to 
chance alone is discussed. While the results of this study do not disprove 
the hypothesis that women with positive screening tests and negative 
OGTTs are at an early stage of prediabetes, they reassure the practitioner 
that such women do not have significantly increased morbidity of pregnancy. 
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Gestational diabetes is a disorder of carbohydrate metabolism 
limited to pregnancy. Women with the disorder demonstrate normal glucose 
metabolism prior to and subsequent to the pregnancy. 
Gestational diabetes is recognized as an important factor in 
increasing perinatal morbidity and mortality rates. Therefore, 
obstetricians have advocated a variety of criteria-test combinations 
to help identify gestational diabetics. In many obstetrical practices 
and clinics women fulfilling certain criteria are screened for abnormal 
glucose metabolism. The screening test usually yields a fasting blood 
glucose level and a post-prandial level. If the latter is above 
a certain limit, the screening test is considered positive, and a 
full 3 hour glucose tolerance test (GTT) is performed to further assess 
the woman's carbohydrate metabolism. If the GTT results are abnormal, 
the woman is considered a gestational diabetic and is managed accordingly. 
On the other hand, if the GTT results are within normal limits, the 
screen is thought of as falsely positive, and she is managed as a normal 
gravida. No studies have proved that this group of women does not 
differ from women who have negative screening test results, in terms 
of complications and outcome of pregnancy. It is the objective of 
this study to compare two such groups of women with respect to a 




Gestational diabetes was first recognized as an entity in the 
1920'sJ However, it was not until decades later that physicians re¬ 
alized its association with increased rates of fetal and maternal morbidity 
2 
and mortality. In a retrospective study published in 1946, Miller 
noted that in the years preceding the development of overt diabetes, 
women had an increased risk of delivering a macrosomic baby (^ 4500gm), 
and/or losing the infant in a perinatal death. These women were considered 
prediabetics with borderline (but normal) carbohydrate metabolism, a state 
that might change to overt diabetes with increased diabetogenic stress 
and/or time. 
Over the last two decades, pregnancy has been recognized as a 
3 
diabetogenic factor, and the pathophysiology of gestational diabetes 
4 
has been elucidated. During pregnancy, two major factors cause an 
alteration in the distribution of energy substrates. The first is the 
fetus being the passive recipient of glucose (transported across the 
placenta by facilitated diffusion), and of actively transported amino 
acids. The second is the placental secretion of contrainsulin factors 
that render the body tissues somewhat "resistant" to insulin. The normal 
pancreas compensates for this decreased effectiveness of insulin by 
increasing its secretion. In the gestational diabetic, the functional 
reserve of the islet cell may be inadequate to fulfill the increased 
demand, and hyperglycemia becomes evident. 
A widely accepted hypothesis that links maternal hyperglycemia 




mothers is the hyperglycemia-hyperinsulinemia hypothesis. It suggests 
that many of the complications are caused by fetal hyperinsulinemia. It 
is thought that maternal hyperglycemia results in fetal hyperglycemia, and 
this in turn, induces hypertrophy and hyperplasia of the fetal islet cells 
and fetal hyperinsulinemia. The excess fetal insulin acts as a growth 
hormone, causing increased fat and glycogen deposition, as well as visceromegaly. 
Oakley et alJ in a study published in 1972, suggested that fetal hyperinsuli- 
nemia and possible subsequent hypoglycemia (e.g. in a fasting state) might 
contribute to the increased perinatal mortality rates associated with 
diabetes. Fetal hyperinsulinemia has also been implicated in causing 
O 
neonatal hypoglycemia. After birth, the infant is no longer exposed to 
the high levels of glucose present in the diabetic mother's blood. The 
g 
neonate's hyperinsulinemia causes rapid decline in the blood glucose level. 
Glycogen stores are not mobilized rapidly due to attenuated catecholamine 
secretion in such neonates.^ The combination of the two factors causes 
hypoglycemia in the infant of the diabetic mother. 
A report published by Smith et al (1975)^ helped support the notion 
that fetal hyperinsulinemia may be a factor in increasing the incidence 
of another complication, the respiratory distress syndrome, among infants 
12 
of diabetic mothers. Insulin was reported to interfere with the synthesis 
of lecithin by cultured fetal lung cells.^ 
If the hyperglycemia-hyperinsulinemia theory is valid, then the 
morbidity rates associated with diabetic pregnancies should be reducable 
with tight metabolic control of the pregnant diabetic. This has been 
1 ^-1 fi 
supported by a number of studies. 

-4- 
Screening for Gestational Diabetes: 
Since the recognition of the association of gestational diabetes 
with increased rates of maternal and fetal morbidity and mortality, 
the importance of identifying gestational diabetics has been undisputed. 
To detect all cases of gestational diabetes, all pregnant women would 
have to undergo a GTT. However, since only a small percentage of the 
tests would yield positive results, cost-effectiveness (financial and 
otherwise) would render such an endeavor unjustified. Therefore, 
criteria were needed for the selection of those women who should undergo 
a GTT. 
Many criteria-test combinations for the detection and diagnosis 
of gestational diabetes have been advocated. The criteria used for 
"diabetic testing" have been those of positive history of glycosuria, 
obesity, spontaneous abortions, polyhydramnios, stillbirth, toxemia, 
excessive weight gain in pregnancy, recurrent prematurity, large for 
gestational age offspring, a newborn with congenital anomaly, and/or 
17-22 
family history of diabetes. It has been suggested that any 
woman fulfilling any of these criteria should undergo a GTT during 
each trimester of pregnancy. It has been thought that the greater 
the number of criteria that a woman fulfilled, the higher her chances 
23 
of developing gestational diabetes were. 
Among the variety of tests used to screen for or diagnose 
gestational diabetes have been 1 hour post-prandial blood glucose 
24 25-26 
measurements, 2 hour post-prandial blood glucose measurements, 
27 ? q 
intravenus GTT, and oral GTT (OGTT). Also, different glucose 
24 
loads (e.g. 50gm, 75gm, etc.) have been used. In 1973 O'Sullivan et al 

suggested the use of a one hour screening test for the selection of 
those women that should undergo a three hour GTT. Their proposal was 
based on the study of 752 pregnant women, all of whom underwent a 1 hour 
screening test and a 3 hour OGTT. In the screening test described, the 
subject ingested 50 grams of glucose, and 1 hour later a venous whole 
blood glucose was obtained. A threshold value of 130 mg/dl was decided 
upon, and if this, threshold was reached or exceeded, a glucose tolerance 
test was suggested. When comparing the efficacy of using the 1 hour 
screening test as compared to historical data as criteria for GTT ad¬ 
ministration, it was noted that a greater percentage of gestational 
diabetics (78.9% vs. 63%) were identified by the screening tests while 
fewer GTT's would be necessary (14.5% vs. 44.5%). 
Criteria for OGTT: 
Because of the physiological changes during pregnancy, normal 
pregnant women manifest a different pattern of glucose tolerance from 
29 
that of non-pregnant women. Therefore, criteria were needed to define 
28 
abnormal glucose tolerance in pregnancy. In 1964, O'Sullivan and Mahan 
published a suggested set of criteria based on the results of lOOgm 
3 hour OGTTs given to 752 women. The upper limit of normal was set at 
2 standard deviations above the mean for each of the four whole venous 
blood glucose levels obtained during the test. The levels suggested 
were: fasting, 90 mg/dl; 1 hour, 165 mg/dl; 2 hour, 145 mg/dl; and 
3 hour, 125 mg/dl. If any two of these limits were reached or exceeded, 
the GTT was considered positive. In this study, 255 women who had 
positive GTTs were followed. Within 8 years, 22.6% of these women were 
overt diabetics in the non-pregnant state, and by 16 years 60% of them 
■ 
were diabetic. These long-term follow-up results have helped validate 
the proposed criteria, which are now widely accepted as standards. 
Women who demonstrate a positive OGTT are identified as gestational 
diabetics. Controversy exists over the manner in which their diabetes 
should be managed. Some authorities advocate their placement in high- 
risk pregnancy clinics, administration of dietary therapy and/or insulin 
therapy, measurement of urinary estriols, non-stressed antepartum 
monitoring, oxytocin challenge tests, lecithin to sphingomyelin ratio 
(L:S), early delivery, and close observations of the neonate in the 
first few hours of life with early feeding.13,30-36 f-jn(j some 0f 
these measures unnecessary. However, most authorities agree that women 
with positive GTT results should not be treated as routine gravidas. 
Women that have positive screening test results and negative 
GTT results are generally considered normal gravidas and treated as such 
However, on at least one occasion, these women have demonstrated possibl 
evidence of abnormal or borderline glucose metabolism (a blood glucose 
level of 130 mg/dl or greater during the screening test); they may 
have as many as 1 abnormal value and 3 borderline ones among the GTT 
results. It may be suspected that these women do not have fully normal 
carbohydrate metabolism, and that they may be at an early stage of the 
prediabetes-diabetes continuum,therefore exhibiting some abnormality in 
their carbohydrate metabolism, but not sufficient deviation from the 
normal to be considered gestational diabetics. If the above hypothesis 
is true, then the question is raised as to whether these women's 
pregnancies and their outcome are complicated by factors similar to 

gestational diabetics', though may be in a milder form or at a lower 
frequency. Consequently, should these women's pregnancies and newborns 
be monitored more closely than those of the routine gravidas? This 
study addresses this concern. 
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MATERIALS AND METHODS 
In a private practice setting, at Yale-New Haven Medical Center, 
436 women were screened for gestational diabetes between September 1, 1975, 
and May 31, 1980. From this group, women who fulfilled the following 
criteria were included in this study: 
1. A negative screening test, or a positive one followed by a 
negative GTT. 
2. Age >_ 25 years for at least the 3rd trimester of pregnancy 
(for uniformity of the sample; this age group is reported 
37 
to have a higher risk of perinatal mortality). 
3. Delivery at Yale-New Haven Medical Center (for completeness 
of records). 
4. Delivery of a singleton (to eliminate factors that might 
confound the results, such as the increased morbidity 
associated with multiple births). 
Using these criteria, the study sample was composed of 328 women, 77 
(23%) of whom had positive screening test results and negative OGTTs, 
and, 251 (67%) of whom had negative screening tests, and did not undergo 
a GTT. These two groups were compared. 
Screening and OGTT Criteria: In September of 1975, the use of the 50gm 
24 
glucose 1 hour screening test described by O'Sullivan et al in 1973, 
was adopted at Yale-New Haven Medical Center. Since O'Sullivan et al 
had reported that, among women over 25 years of age, there is an increased 
37 risk of perinatal mortality associated with gestational diabetes, 

it was decided to screen all women over that age. As for women under 
25 years, only those that had any of the historical criteria mentioned 
in the previous section were to be screened. 
At Yale-New Haven Medical Center, a 1 hour glucose level of 130 
mg/dl or above is considered a positive screening test and an OGTT is 
strongly suggested to the patient. The level of 130 mg/dl was that 
suggested by O'Sullivan et al in 1973, using the Somogyi-Nelson method 
and for whole venous blood. At Yale-New Haven Medical Center, where 
the glucose oxidase method is used to report serum glucose measurements, 
the equivalent of the 130 mg/dl value suggested by O'Sullivan et al 
38 would be 143 mg/dl. However, reports by Carpenter and Couston (1981) and 
39 
Amankwahetal (1977) suggested that using the adjusted level for plasma 
glucose (143 mg/dl) may lead to under diagnosis of gestational diabetes. 
Thus, a 130 mg/dl threshold is used. 
As for the OGTT results criteria, those described by O'Sullivan 
28 
and Mahan in 1964 are used at Yale-New Haven Medical Center. However, 
these values are adjusted for the above mentioned factors; therefore, 
instead of using 90 mg/dl for the fasting blood, 165 mg/dl for the 1 
hour level, 145 mg/dl for the 2 hour level, and 125 mg/dl for the 3 hour 
level, 95 mg/dl, 180 mg/dl, 160 mg/dl, and 135 mg/dl are used, respectively. 
Management: Since none of the women in this study had a positive 
GTT, they were followed in the routine manner for normal gravidas - unless 
a complication developed. Therefore, they were seen monthly over the 
first 30 weeks of pregnancy, biweekly between the 30th and the 36th 
weeks, and weekly after the 36th week. 

-10- 
Records of the obstetrical care delivered to the women and the neonatal 
hospital stay of their offspring were reviewed to obtain the data 
for this study. Among the data collected were the following variables: 
Obesity: Using United States National Health Survey tables for 
40 
height and weight, the subjects were divided into subgroups according 
to their weight percentile. Women over the 75th percentile for weight 
were considered obese. 
Beginning Pregnancy Weight: During the first obstetrical visit 
at Yale-New Haven Medical Center women are asked about their pre-pregnancy 
weight and it is recorded. 
Mid-Pregnancy Weight: This measurement is needed to calculate 
the weight percentile of the infant (as described below). The weight 
obtained at the date nearest to 20 weeks was used. In the case of late 
registrants, whose first recorded weight was at 24 weeks of gestation 
or later, a mid-pregnancy weight was approximated by assuming an 
average weight gain of one pound per week during that stage of pregnancy. 
End Pregnancy Weight: The last weight recorded prior to delivery 
was used. If the last weight was recorded more than 14 days prior to 
delivery, no end pregnancy weight was included in the collected data 
for that patient. 
Systolic and Diastolic Blood Pressure Ranges: The maximal and 
minimal systolic and diastolic blood pressures recorded during the 
pregnancy were used to calculate the systolic and diastolic ranges. 
If the highest systolic blood pressure reading was recorded on a different 
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date from that on which the highest diastolic blood pressure reading 
was noted, the set with the highest mean arterial blood pressure was 
used for this study. However, if on the two occasions, the mean 
arterial blood pressure was also the same, the set with the higher 
diastolic reading was chosen. Similar criteria were used to collect 
minimum blood pressure data. 
Gestational Length: By approximating to the nearest week, 
the gestational length was determined using dates - and ultrasound, 
where applicable. 
Mode of Delivery: The information recorded on the "birth sheet," 
a form filled in by the obstetrical nursing staff immediately after 
birth, was used. 
Newborn Special Care Unit (NBSCU): Since the study sample did not 
include women with positive GTT results, pediatricians were not routinely 
called to the delivery room, and neonates were not routinely admitted 
to the NBSCU for observations. However, due to cesarean deliveries or 
complications, such measures were required for some infants. 
. 4i 
Weight Percentile: Using Tanner and Thompson graphs (1970), 
birth weights were adjusted for sex, mother's height, mother's mid¬ 
pregnancy weight, length of gestation, and parity. In cases where the 
mother's mid-pregnancy weight exceeded 80 kilograms, the total birth 
weight adjustment was 0.500 kilograms. 
Congenital Anomalies and Neonatal Complications: Only those 
congenital anomalies and neonatal complications noted during the neonatal 
I 
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hospital stay were included in the data collected for the study. 
Hyperbilirubinemia: Total bilirubin of 15 mg/dl or greater was 
used as the criterion for the presence of hyperbilirubinemia. 
Respiratory Difficulties: All respiratory difficulties that 





Age: Table 1 illustrates the age distribution of the subjects included 
in this study. Thirty-two of 77 (41.6%) of the women in the positive screen 
group and 89 of 251 (35.4%) of the women in the negative screen group 
were over 30 years old. This difference was not statistically significant. 
There was a significantly (p <0.05) greater percentage of women over 
the age of 35 years in the positive screen group (11.7%) than in the 
negative screen group (6.4%). 
Table 1, Age Distribution 
Age 
Pos. Screen 
N = 77 
(No.) (%) 
Neg. Screen 
N = 251 
(No.) (%) 
25-30 45 58.4 162 64.5 
31-35 23 29.9 73 29.1 
36-40 8 10.4 14 5.6 
41-44 1 1.3 2 0.8 
Mean Age 30.5 years 29.7 years 
Race: Table 2 describes the racial distribution of the women in the 
two groups. No significant differences were evident between them. 
Both groups included a high percentage of Caucasians (92.2% and 94.8% 
of the positive and negative screening group, respectively). 
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N = 251 
(No.) (%) 
Caucasian 71 92.2 238 94.8 
B1 ack 4 5.2 10 4.0 
Oriental 2 2.6 3 1.2 
Obesity: Table 3 depicts the distribution of the women in the study sample 
according to their pre-pregnancy weight. A significantly (p < 0.02) higher 
percentage of the women in the positive screen group (15.1%) than in the 
negative screen group (7.8%) were obese (at or above the 75th percentile 
for weight) prior to the pregnancy reviewed. 
Table 3, Maternal Weight Percentile 
Pos. Screen Neg. Screen 
Percentile Range N = 66* N =219* 
(No.) (%) (No.) (%) 
Less than 25 27 40.9 116 53.0 
25-49 21 31 .8 60 27.4 
50-74 8 12.1 26 11.9 
Equal to or greater than 75 10 15.1 17 7.8 
*The records of 11 women with positive screens and 32 women with negative 
screens did not include all the information needed to calculate weight percentiles. 
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Obstetrical History: Table 4 describes the data collected about the 
obstetrical histories of the women in the study sample. No significant 
difference is evident between the two groups with respect to parity. 
46.7% of the women in the positive screen group and 50.1% of the negative 
screen group were nulliparous. 
As for positive obstetrical history for spontaneous abortion(s), 
as illustrated in table 4, a considerable number of the women that had 
positive screens (22/77, 28.6%) had had 1 or more spontaneous abortion 
prior to the pregnancy reviewed. However, when this group was compared 
to the negative screen groups, (55/251, 21.9%), the difference was not 
significant. 














Nul1iparous 36 46.7 126 50.1 
Hx of Sp. Ab. 
0 55 71.4 196 78.1 
1 13 16.9 38 15.1 
2 6 7.8 13 5.2 
3 2 2.6 3 1.2 
4 1 1.3 1 0.4 
Hx of Stillbirth 
0 71 92.2 241 96.0 
1 4 5.2 10 4.0 
2 2 2.6 0 0.0 
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In table 4, the distribution of women in the two groups according 
to the history of any prior stil1 birth(s), is depicted. Among the women 
with positive screens, there was a statistically significant (p <0.05) 
increased frequency of positive history for stillbirths (7.8%) when compared 
to the histories in the negative screen group (4.0%). 
Complications of pregnancy: Table 5 illustrates the patterns of weight 
gain of the two groups. The percentage of women that gained more than 30 lbs 
was very similar for the two groups (53.8% of the positive screen group and 
52.9% of the negative screen group). 
Table 5, Weight Change During Pregnancy 
Pos. Screen Neg. Screen 
Weight gain 
(lbs) 





(No. ) (%) (No. ) (%) 
Less than 20 7 10.8 27 12.2 
20-29 23 35.4 77 34.8 
30-29 19 29.2 82 37.1 
40-49 11 16.9 29 13.1 
50-59 3 4.6 6 2.7 
60 or more 2 3.1 0 0.0 
Mean 32.6 lbs 30.3 lbs 
*The records of 12 women in the positive screen group and 30 women in the 
negative screen group did not include a value for the total amount of weight gain. 
Toxemia is a recognized complication associated with gestational 
42 
diabetes. Therefore differences in blood pressure ranges for the two 
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groups were calculated and compared. Diagnostic criteria for pre- 
43 
eclampsia were used. Table 6 illustrates systolic and diastolic 
blood pressure ranges during pregnancy. In the positive screen group 
16/75 (21.3%) had systolic blood pressure range equal to or greater 
than 30 mm Hg, while 60/251 (23.9%) of the negative screen group showed 
such a range. No statistically significant difference exists. As for 
diastolic blood pressure measurements, the two groups showed no significant 
difference with 34/75 (45.3%) of the positive screen group showing a 
range equal to or greater than 15 mm Hg, while 99/251 (39.4%) of the 
negative screen group demonstrated similar range. 
Table 6, Blood Pressure Ranges 
Blood Pressure Range 
(mm Hg) 
Pos. Screen 
N = 75* 
(No.) (%) 
Neg. Screen 
N = 251 
(No.) (%) 
Systolic BP Range 
Less than 30 59 78.7 191 76.1 
30 or more 16 21.3 60 23.9 
Mean 19.9 21.3 
Diastolic BP Range 
Less than 15 41 54.7 152 60.6 
15 or more 34 45.3 99 39.4 
Mean 14.4 mm Hg 13.4 mm Hg 
*2 women did not have complete blood pressure records. 
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Gestational Length and Mode of Delivery: Diabetics are known 
44 
to have an increased incidence of premature deliveries. However, when 
comparing the positive screen, negative GTT group to the negative screen 
group no significant difference was noted in the incidence of preterm 
(< 37 weeks) deliveries. Nine of 77 (11.7%) of the positive screen group 
and 28/251 (11.2%) of the negative screen group delivered within that period. 
Table 7 illustrates the distribution of gestational length for the two groups. 
Table 7, Gestational Length 














30 1 0.4 
31 1 1.3 
32 1 0.4 
33 1 0.4 
34 1 0.4 
35 1 1.3 6 2.4 
36 3 3.9 7 2.8 
37 4 5.2 n 4.4 
38 13 16.9 21 8.4 
39 21 27.3 53 21.1 
40 13 16.9 85 33.9 
41 13 16.9 45 17.9 
42 7 9.1 18 7.2 
43 1 1.3 1 0.4 
Mean 39.28 (39 2/7 wks) 39.47 (39 3/7 wks) 
Table 8 delineates the frequency of the different modes of del ivery among 
the two groups. The modes were grouped according to the situation that may 
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require a certain method. When comparing the positive screen group of 
women to the negative screen group with respect to mode of delivery, no 
significant difference was noted in the group of modes that may be 
necessitated by a macrosomic baby - namely, mid forceps, vacuum, and 
cesarean section for failure to progress. Eleven of 77 (14.3%) of the 
positive screen group and 40/251 (15.9%) of the negative screen group was 
delivered by such a method. No other statistically significant variation 
was evident between the two groups of women with respect to mode of delivery. 
Table 8, Mode of Delivery 
Pos. Screen Neg. Screen 
Mode of Delivery N = 77 N = 251 
(No.) (%) (No.) (%) 
Spon. Vag. Del., 
Low Forceps Del. 
52 67.5 185 73.7 
Mid Forceps Del., 
Vacuum, FTP C-section 
11 14.3 40 15.9 
Fetal Distress C-section 2 2.6 3 1 .2 
Abnormal lie 6 7.8 7 2.8 
Repeat C-section, 
C-section for Herpes 
6 7.8 16 6.4 
Neonatal Distress: Table 9 depicts the percentage of newborns that had 
an APGAR score of less than 7 at 1 or 5 minutes of life. Of the positive 
screen group 9.1% and 3.9% had APGAR scores of less than 7 at 1 and 5 minutes, 
respectively. Of the negative screen group 8.0% and 2.4% had APGAR scores 
of less than 7 at 1 and 5 minutes, respectively. There are no significant 
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differences in the distribution of APGAR scores or their means when the 
positive and negative screen groups are compared. 
Table 9, APGAR Scores 
Pos. Screen Neg. Screen 
APGAR Scores N = 77 N = 251 
(No.) (%) (No.) (%) 
APGAR @ 1 min less than 7 7 9.1 20 8.0 
APGAR @ 1 min equal 
greater than 7 
to or 70 90.9 231 92.0 
Mean APGAR @1 min 8.35 8.29 
APGAR @ 5 min less than 7 3 3.9 6 2.4 
APGAR @ 5 min equal 
greater than 7 
to or 74 96.1 245 97.6 
Mean APGAR @ 5 min 8.78 8.88 
Table 10 illustrates the distribution of newborns with respect to the 
type of facility to which they were transferred after their birth. Some 
were sent to a well-baby nursery (no NBSCU admission), others were admitted 
to the NBSCU for a 6 hour observation and monitoring period, and the rest 
were admitted to the NBSCU for therapy and close monitoring. Although a 
higher percentage of the positive screen group newborns (18.2%) than the 
negative screen group infants (13.2%) required NBSCU admissions, the 
difference was not statistically significant. 
. 
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Table 10, Admissions to NBSCU 
Pos. Screen Neg. Screen 
Type of Admission to NBSCU N = 77 N = 251 
(No.) (*) (No.) (%) 
No admission 53 68.8 179 71.3 
6 hr. observation 10 13.0 39 15.5 
Admission 14 18.2 33 13.2 
Hyperbilirubinemia is recognized as a neonatal complication associated 
45 
with diabetes in pregnancy. Table 11 depicts the incidence of hyper¬ 
bilirubinemia, of other neonatal complications, and of congenital anomalies. 
Although there was a higher incidence of hyperbi1irubinemia (total bilirubin 
equal to or greater than 15) among the infants of the positive screen group 
(13.0%) when compared to the neonates of the other group (8.0%), the 
difference did not reach statistical significance. 
As for other neonatal complications, as depicted in table 11, the 
incidence of respiratory difficulties was significantly (p <0.02) greater 
among the infants of the positive screen group (8/77, 10.4%) in comparison 
to those of the negative screen group (5/251, 2.0%). Hypoglycemia (abnormally 
low Dextrostix^ readings) was noted in 1/77 (1.3%) of the positive screen 
group newborns and in 2/251 (0.8%) of the negative screen infants. It 
should be noted that since none of the women in this study had abnormal 
0GTT results, blood glucose measurements of any kind were not performed 
unless the infant's symptoms suggested that he/she might be suffering from 
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hypoglycemia. Six other infants of the negative screen group had 
neonatal complications of miscellaneous nature (e.g. sepsis, irregular heart 
beat, etc.) that are unlikely to be related to the mother's carbohydrate 
metabolism. 
There is an increased incidence of congenital anomalies among the 
46-48 
infants of diabetic mothers. However, in comparing the positive 
screen and the negative screen groups studied here, no significant difference 
in the incidence of congenital anomalies was apparent. Among the positive 
screen group neonates, 3/77 (3.9%) had congenital anomalies. The anomalies 
were: a preauricular skin tag, bilateral congenital hydrocele of the scrotum, 
and blisters of unknown etiology on the hands of the third baby (healed 
spontaneously). Among the negative screen group infants, 10/251 (4.0%) 
had congenital anomalies and they ranged from a hip click to a question of 
ventricular septal defect. 
Table 11, Neonatal Complications and Congenital Anomalies 
Pos. Screen Neg. Screen 
Complications & Anomalies N = 77 N = 251 
(No.) (%) (No.) (%) 
Hyperbi1irubinemia 10 13.0 20 8.0 
Respiratory Difficulties 8 10.4 5 2.0 
@ 
Dextrostix reading _< 45 1 1.3 2 0.8 
Sepsis 0 0.0 4 1 .6 
Other Complications 0 0.0 2 0.8 
Congenital Anomalies 3 3.9 10 4.0 
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Birth Weight and Neonatal Size: Table 12 delineates the distribution 
of birth weights. Among the women with positive screens there was a 
significantly (p <0.02) higher incidence of neonates weighing 4000 
grams or more. Eleven of 77 (14.3%) of the neonates of this group weighed 
4000 gms or more while only 19/251 (7.6%) of the negative screen neonates 
were in the same weight range. 
Table 12, Birth Weight 
Pos. Screen Neg. Screen 
Birth Weight 
(grams) 
N = 77 N = 251 
(No.) (%) (No.) (%) 
Less than 2000 1 1.3 3 1.2 
2000-2999 12 15.6 57 22.7 
3000-3999 53 68.8 172 68.5 
4000 or more 11 14.3 19 7.6 
Mean 3403. 4 grams 3285 .7 grams 
Despite this difference in the incidence of newborns weighing 4000 
grams or more, no significant difference in the numbers of infants above 
the 75th percentile was seen between the two groups when the birth weights 
were adjusted for sex, mother's height and mid-pregnancy weight, gestational 
age, and parity (Tanner and Thompson ^ graphs used). Table 13 
depicts the distribution of newborns according to weight percentile. 
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Table 13, Birth Weight Percentile Distribution 
Pos. Screen Neg. Screen 
Percentile Range 
(%) 
N = 76* N = 250* 
(No.) (%) (No.) (%) 
Less than 25th 21 27.6 85 34.0 
25-49 25 32.9 81 32.4 
50-74 17 22.4 49 19.6 
Greater than 74th 13 17.1 35 14.0 
*2 subjects with positive screens and 1 with negative screen did not 
have all information needed for the calculation of these percentile values. 
Another measure of macrosomia is that of body fat. The ponderal 
index was used as such a measure. The ponderal index is equal to the 
ratio of the weight in pounds to the value of the length in centimeters 
cubed. The index was calculated for each infant. A table by Miller and 
49 
Merritt was used to obtain the percentile ranges. Table 14 depicts 
the distribution of the values obtained and the percentile range for 
each category. No significant differences were evident when comparing 
















(No. ) (%) (No.) (*) 
Less than 2.41 (25%) 20 30.8 71 32.4 
2.41-2.53 (25-49%) 11 16.9 39 17.8 
2.54-2.67 (50-75%) 11 16.9 41 18.7 
Greater than 2.67 (75%) 23 35.4 68 31.1 
Mean 2. 
_3 
558 gm cm 2.554 gm cm ^ 
*12 newborns of the positive screen group and 32 of the negative screen 
group did not have lengths recorded in their charts. 
Results of QGTT vs. Birth Weight and Weight Percentile: Table 15 depicts 
the distribution of the subjects that had positive screening test results 
according to the presence of an abnormal glucose level, and the number 
of borderline values (within 10 mg/dl of the upper limit for normal), 
present in the OGTT results. Also in table 15, an attempt is made to 
investigate the presence of a correlation between the results of the 
OGTT and the outcome of the pregnancy. In each category of abnormal or 
borderline values, the number of newborns weighing 4000 grams or more 
and/or being in the 75th percentile or above is depicted. Of interest, 
none of the 3 infants whose mothers had 1 abnormal value and 2 borderline 
ones was large by the criteria used, while 20.6% of the women that had no 
abnormal or borderline values in the OGTT results delivered large babies 
by either or both of the criteria used. No correlation between the OGTT 
results and the weight of the baby was evident. 
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Table 15, OGTT Results vs. Birth Weight and Weight Percentile 
OGTT Results 
(points) 
No. of newborns 
with weight >_ 4000 gm 







1 Abnl. +2 Borderline 0 3 0.0 
1 Abnl. +1 Borderline 1 4 25.0 
1 Abnl. 2 9 22.2 
3 Borderline 0 3 0.0 
2 Borderline 1 4 25.0 
1 Borderline 3 14 21.4 
0 Abnl. 0 Borderline 7 34 20.6 
*The records of 6 subjects did not include all the information necessary 




In this retrospective study, a group of pregnant women having 
positive screens and negative OGTTs was compared with a group of women 
having negative screens. Since the women in both groups had been con¬ 
sidered routine gravidas, it was assumed that there had been no bias 
in the type of health care delivered to them. Differences noted between 
the two groups were considered statistically significant if the calculated 
p was less than 0.05. This meant that the likelihood for a significant 
difference to appear due to chance alone was 1 in 20. Therefore, for 
every 20 variables studies, 1 statistically significant difference 
might appear randomly. 
Given that 37 variables were considered in this study, it is 
conceivable that the two groups might differ with respect to two variables 
on the basis of chance alone. However, they differed with respect to 5 
variables, approximately twice the predicted number. In addition, the 
difference noted depicted variations in the direction that would be 
expected if the hypothesis proposed was valid. Were chance alone the 
cause of the noted differences, it would have been unlikely for all the 
differences to support the hypothesis. The number of variables with 
respect to which differences were noted, and the general trend of these 
differences, favor the notion that the two groups intrinsically differ 
in certain respects. Some of the variables examined are discussed below. 
Age: In 1968, Grimaldi reported that the prevalence of gestational 
50 
diabetes is significantly greater among women over the age of 30 years. 
Other investigators have reported that the mean age of gestational diabetics 
51 -52 




tendency exists with 11.7% of the women in the positive screen group 
being over the age of 35 years as compared to 6.4% of the negative 
screen group. However, the mean age of the women in the two groups was 
not significantly different. It is tempting to consider these results 
as supportive of the proposed hypothesis. 
51 
Obesity: Gestational diabetes has been related to obesity. If 
subjects with a positive screening test and a negative GTT are part 
of the prediabetes continuum, obesity might be more common in this group 
of women compared to those with a negative screening test. In the present 
study, such a relationship did exist, with 15.1% of the positive screen group 
being above the 75th percentile for pre-pregnancy weight as compared to 
7.8% of the negative screen group. 
Obstetrical History: In 1966, Dandrow and O'Sullivan reported a 
significant difference in parity between gestational diabetics and non¬ 
diabetics (mean parity among gestational diabetics was 4.2 while that of 
51 
the nondiabetics was 2.2). Other reports have pointed to similar 
52 
observations. Therefore, women in the two groups of this study were 
compared to investigate the presence of an association between parity 
and the incidence of positive screens and negative OGTT. With the two 
groups having similar numbers of multiparous and nulliparous women in 
them, no such association was evident. 
The incidence of spontaneous abortions among diabetic women is 
53 
thought to be the same as that of the general population. However, 
the former group demonstrates an increased incidence of intrauterine 
51 54 
deaths. ’ The two groups studied here demonstrated no significant 
difference with respect to the incidence of history for spontaneous abortion(s). 
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However, 7.8% of the positive screen group versus 4.0% of the negative screen 
group had a positive history of stillbirth(s) - a significant difference. 
These results are consistent with those expected if the hypothesis proposed 
in this study were valid. 
Complications of pregnancy: It may be suspected that pregnant 
women who gain an excessive amount of weight ( .>30 lbs.) are more likely 
to have a positive screening test than women that undergo a smaller amount 
of weight gain. The results of this study did not confirm this suspicion. 
53.8% of the positive screen group and 52.9% of the negative screen group gained 
30 or more pounds. 
Preeclampsia is reported to occur at higher rates among diabetics 
42 
than nondiabetics. In this study, blood pressure ranges were used as 
indicators of possible preeclampsia. The two groups were compared with 
respect to the range of the systolic blood pressure readings and to that 
of the diastolic blood pressure readings. In calculating the range for 
systolic blood pressure for a specific subject, the maximum and the minimum 
blood pressure measurements were compared. These two values might have 
been recorded at any time during the pregnancy, and one or both of them 
might have been atypically high or low for the patient's usual blood pressure 
readings. The same was true for diastolic blood pressure range calculations. 
Adapting accepted criteria for the diagnosis of preeclampsia to the present 
43 
study, a value 30 mm Hg for systolic blood pressure range and a value 
^ 15 mm Hg for diastolic blood pressure range were used as criteria for 
comparison of the two groups. No significant difference was evident. 
The frequencies of women meeting these criteria may seem high for both 
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the negative and the positive screen group (23.3% of the total study 
sample met the criteria for large systolic blood pressure range and 
40.8% met the criterion for large diastolic blood pressure range). 
However, it should be noted that these frequencies do not indicate the 
true incidence of preeclampsia. Considering the method in which these 
frequencies were obtained, it is evident that their significance is not 
in their absolute values, but rather in their being a measure of comparison 
for the two groups. 
Gestational length and neonatal complications: Prematurity and 
its associated complications are well known causes of increased neonatal 
55-56 morbidity and mortality among the infants of diabetic mothers. 
The two groups in this study were compared with respect to gestational 
length. No correlation between positive screens (that were followed by 
negative OGTTs) and prematurity was evident. 11.7% and 11.2% of the 
positive screen group and of the negative screen group, respectively, 
gave birth during or before the 37th week of gestation. In addition, 
there was no significant difference between the two groups in the number 
of neonates with APGAR scores of less than 7 at 1 or 5 minutes. 
Hyperbi1irubinemia occurs with greater frequency among the newborns 
of diabetics than among the newborns of nondiabetics.56-58 The mechanism 
57 56 for the increased incidence is not well understood. Prematurity, 
59 the use of oxytocin to induce vaginal delivery, increased extramedullary 
fin 
hematopoeisis and increased hematocrit in macrosomic babies, are some 
of the causal factors that have been implicated. Between the positive 
screen group and the negative screen group no statistically significant 
C 
-3.1 - 
difference was noted with respect to the incidence of hyperbilirubinemia. 
Respiratory distress syndrome (RDS) of the neonate is another 
12 
complication associated with diabetic pregnancies. However, with 
the use of the L:S ratio before delivery, and other factors (possibly 
including improved maternal diabetic control), the incidence of neonatal 
57 
RDS in the infants of diabetics is decreasing. The two groups in this 
study were compared with respect to respiratory difficulties that necessitated 
admissions to the NBSCU. 10.4% of the neonates of the positive screen 
group had such difficulties while only 2.0% of the negative screen group 
did. This is a statistically significant difference (p <0.02). However, 
when the two groups were compared with respect to the incidence of the neonatal 
diagnosis of RDS, no significant difference was apparent (2/77 neonates in 
the positive screen group and 2/251 of the neonates in the negative screen group). 
As for neonatal hypoglycemia, a well recognized neonatal complication of 
diabetic pregnanciesthere was no significant difference in its 
incidence between two groups compared in this study. 
Congenital Anomalies: Most authorities agree that congenital anomalies 
occur with increasing incidence in the newborns of diabetic mothers 
4 46-48 
when compared to newborns of nondiabetics. 5 As antenatal and 
perinatal care improves, congenital anomalies are causing an increasing 
62 
proportion of the neonatal mortality rate among infants of diabetic mothers. 
In this study, no significant difference was noted in the incidence of 
congenital anomalies, when the neonates of the positive screen group were 
compared to those of the negative screen group. Three of 77 newborns in 
the positive screen group had minor anomalies (a preauricular skin tag. 
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a bilateral congenital hydrocele of the scrotum, and blisters of 
unknown etiology on the hands). This low rate of congenital anomalies 
is not surprising in view of the fact that gestational diabetics have a 
lower incidence of congenital anomalies than overt diabetics. Women 
with positive screening tests and negative OGTTs would be expected to 
have even lower rates than gestational diabetics. 
Macrosomia: Macrosomia (defined by most investigators as a birth 
weight equal to or greater than a specific weight, usually between 3500 
and 4500 grams) is a common complication associated with diabetic 
4 36 
pregnancies. ’ Godel et al reported that infants born to diabetic mothers 
between the 35th and 39th week of gestation, weigh about 500-600 grams more 
63 
than infants of nondiabetic mothers of similar gestational age. Among 
macrosomic infants, traumatic morbidity during vaginal delivery resulting 
64 
in shoulder dystocia, Erb's palsy, and broken bones is increased. 
Therefore, it is important to identify women who are likely to give birth 
to macrosomic infants. In this study, the mean birth weight of the 
neonates in the positive screen group was not significantly different from 
that of the neonates of the negative screen group. However, the former 
group had a significantly higher percentage of babies (14.3%) weighing 4000 
grams or more as compared with the latter group (7.6%). The disparity 
in the incidence of macrosomic infants ( >_ 4000 grams) between the two 
groups may be secondary to factors other than carbohydrate metabolism 
(e.g. gender, maternal obesity). Boys tend to have somewhat larger 
65 
birth weights than girls. Since there was a higher percentage of boys 
among the neonates of the positive screen group (62.3%), than among those 
of the negative screen group (50.6%), a higher incidence of macrosomic 
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babies would be expected among the positive screen group than among the 
negative screen group. In addition, obese women are known to deliver 
larger babies than normal weight women of the same height. Therefore, 
another factor is the fact that there was a higher incidence of obesity 
among the women in the positive screen group than the negative screen one. 
Both maternal obesity and neonatal gender can be corrected for 
41 
in calculating birth weight percentiles. Tanner and Thompson graphs 
were used and percentiles were calculated after adjusting the birth weights 
for maternal mid-pregnancy weight, height, parity, neonatal sex, and 
gestational age. There was no difference between the two groups in the 
incidence of babies in the 75th percentile or above it. These findings 
suggest that women in the positive screen group are more likely to deliver 
macrosomic babies due to maternal obesity or other reasons not necessarily 
directly related to carbohydrate metabolism. 
Macrosomic babies of diabetic mothers have high fat content in their 
66 
bodies. The ponderal index is often used in assessing macrosomia, 
49 
because it is an indicator of body fat content. The index was calculated 
49 
and a table by Miller and Merritt was used to estimate the ponderal index 
percentile value for each neonate. There were similar numbers of neonates 
above the 75th percentile in the two groups. These findings suggest that 
the infants of women who have positive screens and negative GTTs are not 
more likely to have high fat content than the infants of women that have 
negative screens. 
Mode of delivery: If women with positive screens and negative OGTTs 
have an increased incidence of delivering macrosomic infants, then an 
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increase in the frequency of operative delivery might be expected (i.e. 
mid forceps deliveries, vacuum extractions, and cesarean deliveries for 
failure to progress). With respect to the rate of use of these methods of 
delivery, no significant difference was noted between the positive screen 
group (14.3%) and the negative screen group (15.9%). 
GTT results and pregnancy outcome: If some of the women that have 
positive screens and negative OGTTs are at risk for a higher incidence 
of perinatal morbidity and mortality, it would be helpful if they could be 
identified by using their OGTT results. Table 15 demonstrates no correlation 
between the results of the OGTT (the presence of one abnormal value and/or 
borderline level(s)) and the weight of the newborn. 
In summary, in comparing a group of women with positive screening 
tests and negative OGTTs to a group of women with negative screening 
tests, no significant differences were noted with respect to racial dis¬ 
tribution, parity, history of spontaneous abortion(s), weight gain during 
pregnancy, blood pressure range, gestational length, modes of delivery, 
APGAR scores, NBSCU admissions, incidence of hyperbilirubinemia, incidence 
of RDS, incidence of neonatal hypoglycemia, congenital anomalies, weight, 
percentile, or ponderal index. However, statistically significant 
differences were evident with respect to the presence of women over the 
age of 35 years, obesity, history of stillbirth(s), incidence of neonatal 
respiratory difficulties, and of birth weight >_ 4000 grams. 
Considering that the two groups demonstrated significant differences 
with respect to 5 variables, 2 of which may have been due to random change 
(as discussed previously), the findings of this study do not prove or 
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disprove the hypothesis proposed (that the women with positive screens 
are at an earlier stage of the prediabetes-diabetes continuum than 
gestational diabetics). The few differences found, if not due to chance, 
are not significant enough for one to consider women with positive screens 
and negative OGTTs abnormal. Actually, the results of this study offer 
the practitioner added support in reassuring women that a positive screening 
test followed by a negative OGTT is not associated with significant increase 
in the morbidity of the pregnancy. 
It may be argued that the positive findings of this study could be 
viewed as indicators that the carbohydrate metabolism of women with positive 
screens and negative OGTTs is different from that of normal women, and 
therefore, these women may be at an early stage of prediabetes. Whether 
this argument is valid can be determined through long term follow-up 
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